ReviewNature reviews. Gastroenterology & hepatology2018
New treatments and therapeutic targets for IBS and other functional bowel disorders.
Review in Nature reviews. Gastroenterology & hepatology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05453084 (Evaluation of the Effectiveness of a Physical Exercise Intervention on Quality of Life and Symptom Profile of Patients With Irritable Bowel Syndrome), which is not on this map. Cited by 60 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of the Effectiveness of a Physical Exercise Intervention on Quality of Life and Symptom Profile of Patients With Irritable Bowel Syndrome (IBS).
Who cites it
60 citing papers in PubMed, 3 syntheses or guidelines pooled it, 138 citations in OpenAlex.
- The Safety of Pharmacotherapy for Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis.The American journal of gastroenterology · 2026Pooled it
- Improvement of irritable bowel syndrome with glucagon like peptide-1 receptor agonists: a systematic review and meta-analysis.Frontiers in endocrinology · 2025Pooled it
- The efficacy of vitamin D supplementation for irritable bowel syndrome: a systematic review with meta-analysis.Nutrition journal · 2022Pooled it
- Effects of Cannabidiol Chewing Gum on Perceived Pain and Well-Being of Irritable Bowel Syndrome Patients: A Placebo-Controlled Crossover Exploratory Intervention Study with Symptom-Driven Dosing.Cannabis and cannabinoid research · 2022Trial
- Sensory Adaptation Training or Escitalopram for IBS With Constipation and Rectal Hypersensitivity: A Randomized Controlled Trial.Clinical and translational gastroenterology · 2021Trial
- Trial
- Irritable bowel syndrome management: current insights.Singapore medical journal · 2026Article
- Clinical Guidance and Practical Recommendations for Probiotic Use in Patients With Irritable Bowel Syndrome, Functional Constipation, andJournal of neurogastroenterology and motility · 2026Review
- Clinical guidance and practical recommendations for probiotic use in patients with irritable bowel syndrome, functional constipation, and Clostridioides difficile infection considering sex-based differences: a Korean translation.Ewha medical journal · 2026Article
- Dietary Behaviors, Digestive Symptoms, and Neurovegetative Features in Disorders of Gut-Brain Interaction: A Cross-Sectional Clinical Study.Nutrients · 2026Article
- Application of neuromodulation techniques in irritable bowel syndrome.Frontiers in neuroscience · 2026Review
- Protective Role of Nano-encapsulated Bifidobacterium breve, Bacilllus coagulans, and Lactobacillus plantarum in Colitis Model: Insights Toward Propagation of Short-Chain Fatty Acids and Reduction of Exaggerated Inflammatory and Oxidative Response.Probiotics and antimicrobial proteins · 2025Article
- Polysaccharides fromNutrients · 2025Review
- Impact of Enhanced Dietary Education Program on Gastrointestinal Symptoms in Patients With Functional Gastrointestinal Disorders: A Multicenter Prospective Pilot Study.Journal of neurogastroenterology and motility · 2025Article
- The diagnostic criteria for psychosomatic research-revised (DCPR-R) in a National China multicenter cohort of patients with irritable bowel syndrome and overlapping gastroesophageal reflux disease.BMC gastroenterology · 2025Article
- Microbiome: A Key Regulator of Body-Brain Interactions.Advances in experimental medicine and biology · 2025Review
- A Synbiotic Combining Chitin-Glucan andInternational journal of molecular sciences · 2024Article
- Examining interactions of illness perceptions, avoidance behavior and patient status in predicting quality of life among people with irritable bowel syndrome.Health psychology and behavioral medicine · 2024Article
- Evaluation of dietary quality in patients with functional gastrointestinal symptoms: a Norwegian single centre study.Food & nutrition research · 2024Article
- Necrotizing Enterocolitis and the Preterm Infant Microbiome.Advances in experimental medicine and biology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Functional bowel disorders (FBDs) are a spectrum of disorders characterized by combinations of symptoms attributable to the lower gastrointestinal tract. Most current first-line therapies for IBS and other FBDs target the predominant symptom and mainly affect one symptom in the symptom complex. Additional broadly effective treatment alternatives targeting the entire symptom complex are needed. New drugs for FBDs (such as lubiprostone, linaclotide, plecanatide, prucalopride, eluxadoline and rifaximin) target key mechanisms in the pathophysiology of these disorders and improve both the abnormal bowel habit and other key symptoms, such as abdominal pain and bloating. The current development of new treatment alternatives is focusing on different aspects of the complex pathophysiology of IBS and other FBDs: gut microenvironment (via diet and modulation of gut microbiota), enterohepatic circulation of bile acids, gastrointestinal secretion, motility and sensation, gut-brain interactions, gut barrier function and the immune system within the gastrointestinal tract. Studies also suggest that personalized treatment of IBS and other FBDs is possible using various diagnostic markers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.